Physician profile
David T Brown
NPI 1700888708
$8,441.29
in general payments reported to CMS, 2019-2025
32 companies · $1,229 in 2025
The $1,229 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $1,126 · 2021: $1,559 · 2022: $1,285 · 2023: $1,621 · 2024: $1,213 · 2025: $1,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,050 · Entertainment: $13.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,049.62 |
| Entertainment | $13.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,446.95 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $829.65 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $743.88 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $660.17 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $640.83 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $602.75 | 2019-2025 | |
| Glaxosmithkline, LLC. | $552.04 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $531.86 | 2019-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $405.18 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $346.23 | 2021-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $280.82 | 2021-2025 | |
| Abbott Laboratories | $244.99 | 2021-2023 | Freestyle Libre 2, Proclaim |
| Merck Sharp & Dohme LLC | $184.64 | 2019-2024 | Verquvo, Belsomra, Capvaxive |
| Sumitomo Pharma America, INC. | $156.24 | 2023-2025 | Gemtesa |
| Esperion Therapeutics, INC. | $97.79 | 2020-2025 | Nexletol |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $85.02 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $78.29 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $68.49 | 2024-2025 | Rexulti, Jynarque |
| Takeda Pharmaceuticals U.S.A., INC. | $63.47 | 2020-2024 | Trintellix |
| Phathom Pharmaceuticals, INC. | $57.32 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $54.31 | 2021 | |
| Dexcom, INC. | $49.76 | 2024-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $44.79 | 2022 | |
| Exact Sciences Corporation | $42.76 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $38.55 | 2020 | |
| Daiichi Sankyo INC. | $31.51 | 2020-2021 | |
| Genentech USA, INC. | $22.53 | 2020 | |
| Amarin Pharma, INC. | $20.54 | 2021 | |
| Inspire Medical Systems, INC. | $17.15 | 2024 | Inspire |
| Vertex Pharmaceuticals Incorporated | $14.67 | 2025 | |
| Nabriva Therapeutics, Plc | $14.46 | 2022 | |
| Optos, INC. | $13.65 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.